82 nd EAS Congress Scientific Programme
|
|
|
- Logan Gaines
- 5 years ago
- Views:
Transcription
1 SCIENTIFIC PROGRAMME (as of March 26, 2014) SATURDAY, MAY 31, :00-13:30 Educational Symposium (Sponsored) Francisco Grande-Covian Hall 14:00-15:30 Educational Symposium (Sponsored) Francisco Grande-Covian Hall 16:00 17:30 Educational Symposium (Sponsored) Francisco Grande-Covian Hall 18:00-19:30 Opening Ceremony including the Anitschkow Lecture Anitschkow Hall Speaker: Prof. John Kastelein, the Netherlands 1
2 08:30-10:30 Plenary Session: Anitschkow Hall MICROBIOTA, IMMUNITY AND REGULATION Chairs: Alberico Catapano, Italy Jesus Millan Nunez-Cortes, Spain 08:30 ROLE OF MICROBIOTA IN ATHEROSCLEROSIS Fredrik Bäckhed, Sweden 09:00 IMMUNITY IN ATHEROSCLEROSIS Ira Tabas, USA 09:30 VACCINATION AGAINST ATHEROSCLEROSIS Johan Kuiper, Netherlands 10:00 ROLE OF micrornas IN ATHEROSCLEROSIS Carlos Fernández-Hernando, USA 10:30 Coffee Break, Exhibition & Poster Viewing 2
3 11:00 12:30 Workshop Session: Amador Schuller Hall Track 1: Vascular biology of the arterial wall 1.2 IMMUNOLOGY OF ATHEROSCLEROSIS Chairs: Jesus Egido, Spain Danilo Norata, Italy 11:00 B CELLS AND HUMORAL IMMUNITY IN ATHEROSCLEROSIS Christoph Binder, Austria 11:25 DENDRITIC CELLS Alma Zernecke, Germany 11:50 THE ROLE OF INNATE IMMUNE RECEPTOR NOD2 IN ATHEROSCLEROSIS Zhang, X., Sweden 12:03 MACROPHAGE-SPECIFIC INACTIVATION OF THE NUCLEAR RECEPTOR ROR-ALPHA LEADS TO INCREASED ATHEROSCLEROSIS IN MOUSE Molendi-Coste, O., France 12:16 NON-INVASIVE IN VIVO IMAGING OF PERIPHERAL MONONUCLEAR CELL MIGRATION TO ATHEROSCLEROSIS IN HUMANS van der Valk, F., Netherlands 3
4 11:00 12:30 Workshop Session: Francisco Grande-Covian Hall Track 2: Lipid and lipoprotein metabolism 2.3 THE LIVER-INTESTINE AXIS IN LIPID METABOLISM Chairs: TBA Gerhard Kostner, Austria 11:00 INTESTINAL TRANSPORTERS, TICE Bert Groen, The Netherlands 11:25 CHOLINE AND CARNITINE METABOLISM Max Nieuwdorp, The Netherlands 11:50 INDUCTION OF LDL RECEPTOR MRNA DEGRADATION FACTOR HNRNPD CONTRIBUTES TO THE CHOLESTEROL-MEDIATED SUPPRESSION OF LIVER LDL RECEPTOR EXPRESSION Liu, J., USA 12:03 HEPATIC DE NOVO LIPOGENESIS AND FAT OXIDATION PREDICT THE POSTPRANDIAL RESPONSE OF TRIGLYCERIDE-RICH LIPOPROTEIN PARTICLES IN HEALTHY SUBJECTS Matikainen, N., Finland 12:16 RNF20 IS A KEY PLAYER IN PKA-DEPENDENT SREBP1C DEGRADATION IN HEPATIC LIPID METABOLISM KIM, J.B., Korea 4
5 11:00 12:30 Workshop Session: Manuel de Oya Hall Track 3: Risk factors, epidemiology, prevention, and treatment of cardiovascular disease 3.3 GENE-ENVIRONMENT INTERACTIONS AND EPIGENETICS Chairs: Fernando Civeira, Spain Ruth Frikke-Schmidt, Denmark 11:00 GENETIC AND ENVIRONMENTAL FACTORS INFLUENCING NON-TRADITIONAL CARDIOVASCULAR RISK FACTORS Florian Kronenberg, Austria 11:25 MicroRNAs IN HEART DISEASE Thomas Thum, Germany 11:50 TARGETING HDAC3 LIMITS FOAM CELL FORMATION AND IMPROVES ATHEROSCLEROTIC PLAQUE STABILITY Van den Bossche, J., Netherlands SIX-YEAR TELOMERE SHORTENING IS ASSOCIATED WITH INCREASED INCIDENCE OF SUBCLINICAL CAROTID VASCULAR DAMAGE AND CARDIOVASCULAR PROGNOSIS Baragetti, A., Italy 12:16 IRON AS A RISK FACTOR FOR ATHEROSCLEROSIS: CONFIRMING THE IRON HYPOTHESIS IN A MOUSE MODEL OF HEMOCHROMATOSIS Vinchi, F., Germany 11:00 11:45 Workshop Session: Anitschkow Hall Track 4: Advanced Clinical Seminars ECTOPIC FAT AS A CARDIOVASCULAR RISK FACTOR Chairs: Vicente Lahera, Spain Philippe Moulin, France 11:00 THE ROLE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN CARDIOVASCULAR DISEASE Sven Francque, Belgium 11:20 OBESITY AND CARDIOVASCULAR RISK Jean Pierre Després, Canada 11:40 DISCUSSION 5
6 11:45 12:30 Workshop Session: Anitschkow Hall Track 4: Advanced Clinical Seminars NEW TARGETS FOR LIPID LOWERING THERAPY Chairs: Juan Pedro-Botet, Spain Chris Packard, UK 11:45 ANTISENSE NUCLEOTIDES Mark Graham, USA 12:05 TRANSCRIPTIONAL REGULATORS Bart Staels, France 12:25 DISCUSSION 12:30-15:00 Lunch Break, Exhibition and Poster Presentations 12:45-13:45 EAS General Assembly (Members Only) Amador Schuller Hall 13:50 14:50 Moderated Poster Session A Exhibition Area 13:00 14:30 Educational Symposium (Sponsored) Manuel de Oya Hall Educational Symposium (Sponsored) Francisco Grande-Covian Hall 6
7 15:00 16:30 Workshop Session: Anitschkow Hall JOINT ESC/EAS SYMPOSIUM: LIPID LOWERING IN CARDIOVASCULA PREVENTION; WHERE DO WE STAND AND WHERE ARE WE GOING? Chairs: Lale Tokgözoglu, Turkey TBA 16:30 Coffee Break and Exhibition REVIEW OF CURRENT STATUS FOR THE GUIDELINES ON DYSLIPIDEMIA COMPARING EUROPEAN AND US GUIDELINES Olov Wiklund, Sweden CHALLENGES FOR FUTURE GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION Guy de Backer, Belgium RISK ESTIMATION AND RISK CALCULATION TBA LOOKING TO THE FUTURE GUIDANCE ON LIPIDS AND OTHER TARGETS Børge Nordestgaard, Denmark 15:00 16:30 Workshop Session: Francisco Grande-Covian Hall Track 1: Vascular biology of the arterial wall 1.4 ENDOTHELIAL CELL BIOLOGY Chairs: Teresa Tejerina, Spain Petri Kovanen, Finland 15:00 REGULATION OF ENDOTHELIAL BARRIER INTEGRITY Asrar B.Malik, USA 15:25 LYMPHATIC VESSELS AND LYMPHANGIOGENESIS Michael Detmar, Switzerland 15:50 TBA 16:03 THE ROLE OF ENDOTHELIAL DICER IN ATHEROSCLEROSIS Hartmann, P., Germany 16:16 THE ADIPOKINE VISFATIN/NAMPT INDUCES PREMATURE SENESCENCE AND TELOMERE DAMAGE IN HUMAN ENDOTHELIAL CELLS Peiro, C., Spain 16:30 Coffee Break and Exhibition 7
8 15:45 16:30 Clinical & Late Breaing Session I Amador Schuller Hall Chairs: TBA 15:45 ATTAINMENT OF THE ANTICIPATED >=50% REDUCTION IN LDL-C IN THE FOUR ACC/AHA GUIDELINES STATIN BENEFIT GROUPS: A VOYAGER META-ANALYSIS Karlson, B., Sweden 15:58 EFFICACY OF EVOLOCUMAB (AMG 145) IN PATIENTS WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS Harada-Shiba, M., Japan 16:11 TRIAL EVALUATING EVOLOCUMAB, A PCSK9 ANTIBODY, IN PATIENTS WITH HOMOZYGOUS FH (TESLA): RESULTS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL Raal, F., South Africa 16:24 THERAPY WITH THE THYROID HORMONE RECEPTOR AGONIST EPROTIROME IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: A RANDOMISED, DOUBLE BLIND, PLACEBO- CONTROLLED STUDY Sjouke, B., Netherlands 17:00-18:30 Educational Symposium (Sponsored) Francisco Grande-Covian Hall 17:00-17:45 Meet the Expert (Sponsored) Manuel de Oya Hall 17:00-17:45 Special Lecture (Sponsored) Amador Schuller Hall 8
9 08:30-10:30 Plenary Session Anitschkow Hall Energy Metabolism and Diabetes Chairs: Jan Borén, Sweden Antonio Gotto, USA 08:30 DIABETIC DYSLIPIDEMIA Marja-Riitta Taskinen, Finland 09:00 REGULATION OF ADIPOGENESIS Ulf Smith, Sweden 09:30 NAFLD and NASH Philip Newsome, UK 10:00 LIPOTOXIC HEART DISEASE Ira Goldberg, USA 10:30-11:00 Coffee Break and Exhibition 9
10 11:00 12:30 Workshop Session: Amador Schuller Hall Track 1: Vascular biology of the arterial wall 1.1 METABOLISM AND FUNCTIONS OF LIPIDS IN VASCULAR CELLS Chairs: TBA Bart Staels, France 11:00 CELLULAR LIPID TRAFFICKING Elina Ikonen, Finland 11:25 SPHINGOSINE-1-PHOSPHATE Roch Nofer, Germany 11:50 LIPOPROTEIN METABOLISM AND TRANSENDOTHELIAL APOLIPOPROTEIN A-I TRANSPORT IN MICE WITH AN ENDOTHELIUM SPECIFIC KNOCK-OUT OF ATP BINDING CASSETTE TRANSPORTER Hasballa, R., Switzerland 12:03 HIV-1 PROTEIN NEF IMPAIRS CELLULAR CHOLESTEROL EFFLUX BY DISRUPTING THE INTERACTION BETWEEN ABCA1 AND CALNEXIN Bukrinsky, M., USA 12:16 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 DEFICIENT MICE ARE PROTECTED FROM NEOINTIMA FORMATION IN CAROTID ARTERY INJURY MODE Nicola, F., Italy 10
11 11:00 12:30 Workshop Session: Francisco Grande-Covian Hall Track 2: Lipid and lipoprotein metabolism 2.4 REGULATION OF DEPOT FAT Chairs: Pedro González Santos, Spain Geesje Dallinga-Thie, The Netherlands 11:00 ABDOMINAL FAT Peter Arner, Sweden 11:25 BROWN ADIPOSE TISSUE Jörg Heeren, Germany 11:50 NON-CANONICAL WNT SIGNALING PROMOTES OBESITY-INDUCED ADIPOSE TISSUE INFLAMMATION AND METABOLIC DYSFUNCTION Fuster, J., USA 12:03 THE INHIBITION OF LYSYL OXIDASE IMPROVES METABOLIC ALTERATIONS AND ADIPOSE TISSUE DISTURBANCES IN OBESE ANIMALS Cachofeiro, Victoria, Spain 12:16 THE LOW-EXPRESSION VARIANT OF FATTY ACID-BINDING PROTEIN 4 FAVORS REDUCED MANIFESTATIONS OF ATHEROSCLEROTIC DISEASE AND INCREASED PLAQUE STABILITY Saksi, J., Finland 11
12 11:00 12:30 Workshop Session: Manuel de Oya Hall Track 3: Risk factors, epidemiology, prevention, and treatment of cardiovascular disease 3.4 ENVIRONMENTAL AND METABOLIC STRESSORS IN CARDIOVASCULAR DISEASE Chairs: Fernando Rodriguez Artalejo, Spain Michal Vrablik, Czech Republic 11:00 STRESS, SOCIOECONOMIC STATUS AND CARDIOVASCULAR DISEASE RISK: AN UPDATE ON CURRENT KNOWLEDGE Mika Kivimäki, UK 11:25 ENVIRONMENTAL AND BEHAVIOURAL RISK FACTORS Fernando Rodríguez-Artalejo, Spain 11:50 CIRCULATING PLASMA FIBROBLAST GROWTH FACTOR-23 IS ASSOCIATED WITH HEMORRHAGIC BUT NOT WITH ISCHEMIC STROKE: RESULTS FROM A GERMAN POPULATION STUDY di Giuseppe, R., Germany 12:03 LACK OF LDL-RECEPTORS PROTECTS AGAINST NEW ONSET TYPE 2 DIABETES - RESULTS OF A COHORT OF 38,000 INDIVIDUALS ANALYZED FOR FH MUTATIONS Besseling, J., Netherlands 12:16 PLASMA SPHINGOLIPID PROFILING REVEALS NOVEL DISTINCT BIOMARKERS FOR PREDICTING CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS Othman, A., Switzerland 12
13 11:00 12:30 Workshop Session: Anitschkow Hall Track 3: Risk factors, epidemiology, prevention, and treatment of cardiovascular disease 3.2 NUTRITION AND NUTRACEUTICALS Chairs: Emilio Ros, Spain Paul Nestel, Australia 11:00 MEDITERRANEAN DIET Emilio Ros, Spain 11:25 NUTRIGENOMICS AND FUNCTIONAL FOODS Helena Gylling, Finland 11:50 EFFECT OF A MEDITERRANEAN DIET INTERVENTION ON 3T MRI-MONITORED CAROTID PLAQUE PROGRESSION AND VULNERABILITY. A SUB-STUDY OF THE PREDIMED TRIAL. Sala-Vila, A., Spain 12:03 IS COMPLYING WITH THE RECOMMENDATIONS OF SODIUM INTAKE BENEFICIAL FOR HEALTH? EVIDENCE FROM THE PREDIMED STUDY Merino, J., Spain 12:16 "CHILDHOOD 25-OH-VITAMIN D LEVELS AND CAROTID INTIMA-MEDIA THICKNESS IN ADULTHOOD. THE CARDIOVASCULAR RISK IN YOUNG FINNS STUDY." Juonala, M., Finland 12:30-15:00 Lunch Break, Exhibition and Poster Presentations Exhibition Area 12:45 13:45 Moderated Poster Session B Exhibition Area 13:50 14:50 Moderated Poster Session C Exhibition Area 13:00 14:30 Educational Symposium (Sponsored) Manuel de Oya Hall 14:00 15:00 Educational Symposium (Sponsored) Francisco Grande-Covian Hall :30 Poster Award Competition Exhibition Area 13
14 15:00 16:30 Joint ICCR/EAS Workshop Anitschkow Hall TARGETING LIFESTYLE IN CVD RISK MANAGEMENT / PREVENTION Chairs: Gabrielle Riccardi, Italy Frank B. Hu, USA OPENING REMARKS Gabrielle Riccardi, Italy FROM NUTRIENTS TO FOOD: KEY FEATURES OF OUR DIET PROVIDING CARDIO PREVENTION Frank B. Hu, USA LESSONS FROM THE PREDIMED TRIAL Emilio Ros, Spain LESSONS FROM LOOK AHEAD Jean-Pierre Després, Canada PHYSICAL ACTIVITY AND CVD RISK Rainer Rauramaa, Finland 14
15 15:00 16:30 Workshop Session Francisco Grande-Covian Hall Track 2: Lipid and lipoprotein metabolism 2.2 NOVEL PROTECTIVE EFFECTS OF HDL Chairs: Arnold von Eckardstein, Switzerland Miranda Van Eck, The Netherlands 15:00 THERAPEUTIC POTENTIAL OF HDL IN CARDIOPROTECTION, CARDIAC REMODELLING, AND HEART FAILURE Bart de Geest, Belgium 15:25 HDL AND ABCA1 IN THE BRAIN Cheryl Wellington, Canada 15:50 A LOSS-OF-FUNCTION MUTATION IN SCARB1 SEVERELY IMPAIRS SR-BI PROCESSING AND ACTIVITY IN HUMANS Zanoni, P., USA 16:03 NOVEL HDL FUNCTIONS ASSOCIATED WITH INTERCELLULAR COMMUNICATION, ATHEROSCLEROSIS, AND CHRONIC KIDNEY DISEASE Vickers, K., USA 16:16 APOLIPOPROTEIN A-I MIMETIC PEPTIDE 4F BLOCKS SPHINGOMYELINASE-INDUCED LDL AGGREGATION: INTERACTION OF THE AMPHIPATHIC HELICAL PEPTIDE WITH LDL PARTICLES Nguyen, S., Finland 15
16 15:00-16:30 EAS Initiatives Update Session (Open to All) Manuel de Oya Hall Chair: Alberico Catapano, Italy Olov Wiklund, Sweden INTRODUCTION/ GENERAL OVERVIEW Alberico Catapano, Italy EDUCATIONAL ACTIVITIES * ACCREDITED DIPLOMA COURSE, * EAS ACADEMY * ADVANCED COURSES Lale Tokgozoglu, Turkey CONSENSUS POSITION PAPERS * PLANT STANOLS AND PLANT STEROLS * TRIGLYCERIDES * HOMOZYGOUS FH * STATIN INTOLERANCE John Chapman, France YOUNG INVESTIGATOR AWARD SESSION Amador Schuller Hall 15: CLINICAL & LATE BREAKING SESSION II Amador Schuller Hall 15:45 RECOMBINANT HUMAN APOLIPOPROTEIN-A-I PREBETA-HDL (CER-001) PROMOTES REVERSE CHOLESTEROL TRANSPORT AND REDUCES CAROTID WALL THICKNESS IN PATIENTS WITH GENETICALLY-DETERMINED LOW HDL Smits, L., Netherlands 15:58 TBA 16:11 MUTATIONS IN ABCA1 ARE ASSOCIATED WITH ENHANCED BETA-CELL SECRETORY CAPACITY IN HUMANS Cuchel, M., USA 16:24 TBA 16
17 16:30-17:00 Coffee Break, Exhibition and Poster Viewing Exhibition Area 17:00-18:30 Educational Symposium (Sponsored) Francisco Grande-Covian Hall 17:00-17:45 Special Lecture (Sponsored) Amador Schuller Hall 17
18 TUESDAY, JUNE 3, :30-10:30 Plenary Session: Anitschkow Hall RISK FACTORS AND INTERVENTIONS Chairs: Olov Wiklund, Sweden John Chapman, France 08:30 CLASSICAL AND NOVEL RISK FACTORS Naveed Sattar, UK 09:00 GENETIC RISK FACTORS AND MENDELIAN RANDOMIZATION Anne Tybjaerg-Hansen, Denmark 09:00 RESIDUAL CARDIOVASCULAR RISK: MANAGEMENT BEYOND STATINS Jane Armitage, UK 09:30 PCSK9 INHIBITION Bertrand Cariou, France 10:30-11:00 Coffee Break, Poster Viewing and Exhibition 18
19 TUESDAY, JUNE 3, :00 12:30 Workshop Session: Amador Schuller Hall Track 1: Vascular biology of the arterial wall 1.3 PLASTICITY OF ATHEROSCLEROTIC LESIONS Chairs: Lina Badimón, Spain Andrew Newby, UK 11:00 METALLOPROTEINASES Andrew Newby, UK 11:25 MACROPHAGE TRAFFICKING Gwendalyn Randolph, USA 11:50 FORKHEAD TRANSCRIPTION FACTOR FOXO3A POTENTLY INDUCES SMOOTH MUSCLE CELL APOPTOSIS AND PROMOTES EXTRACELLULAR MATRIX DEGRADATION THROUGH ACTIVATION OF MATRIX METALLOPROTEINASES Yu, H., United Kingdom 12:03 HEAT SHOCK PROTEIN 27 IS A NOVEL ATHERO-BIOMARKER THAT HALTS ATHEROSCLEROTIC LESION PROGRESSION AND ENHANCES LESION REMODELING O'Brien, E., Canada 12:16 TBA 19
20 TUESDAY, JUNE 3, :00 12:30 Workshop Session: Hall A Track 2: Lipid and lipoprotein metabolism 2.1 GENOMICS AND PROTEOMICS OF LIPID METABOLISM Chairs: TBA Steve Humphries, UK 11:00 GENOMICS (GWAS) Marcello Arca, Italy 11:25 STRUCTURE-FUNCTION RELATIONSHIPS ACROSS HDL PARTICLES AS REVEALED BY PROTEOMICS AND LIPIDOMICS Anatol Kontush, France 11:50 MUTATIONS IN STAP1 ARE ASSOCIATED WITH AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA Fouchier, S., Netherlands 12:03 LOSS-OF-FUNCTION MUTATIONS IN APOC3 AND REDUCED RISK OF ISCHEMIC VASCULAR DISEASE Tybjaerg-Hansen, A. Denmark 12:16 GENETIC DEFECTS IN PROTEIN GLYCOSYLATION AS A CAUSE OF DYSLIPIDEMIA van den Boogert, M., Netherlands 20
21 TUESDAY, JUNE 3, :00 12:30 Workshop Session: Manuel de Oya Hall Track 3: Risk factors, epidemiology, prevention, and treatment of cardiovascular disease 3.1 HYPOLIDAEMIC DRUGS PRESENT AND FUTURE Chairs: Rafael Carmena, Spain Anders Olsson, Sweden 11:00 STATE OF THE ART IN LIPID LOWERING THERAPY Rafael Carmena, Spain 11:25 FUTURE DEVELOPMENTS OF LIPID LOWERING DRUGS Alberto Corsini, Italy 11:50 EFFECT OF ROSUVASTATIN THERAPY ON CAROTID INTIMA MEDIA THICKNESS IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA: FINDINGS FROM THE CHARON STUDY Braamskamp, M., Netherlands 12:03 ALIROCUMAB, MONOCLONAL ANTIBODY TO PCSK9, DOSE-DEPENDENTLY DECREASES ATHEROSCLEROSIS, IMPROVES PLAQUE STABILITY AND SHOWS ADDITIVE EFFECTS WITH ATORVASTATIN IN APOE*3LEIDEN.CETP MICE Van der Hoorn, J., Netherlands 12:16 EFFECT OF SEBELIPASE ALFA AFTER 90 WEEKS IN ADULTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY Tripuraneni, R., USA TUESDAY, JUNE 3, :00 11:45 Workshop Session: Anitschkow Hall Track 4: Advanced Clinical Seminars 4.1 IMAGING OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE Chair: Xavier Pinto, Spain Gil Thompson, UK 11:00 EPIDEMIOLOGICAL AND CLINCIAL EVIDENCE IN FAVOUR OR AGAINST CLINICAL UTILITY OF DIFFERENT PROCEDURES Dan O'Leary, USA 11:20 NOVEL METHODS Erik Stroes, The Netherlands 11:40 DISCUSSION 21
22 TUESDAY, JUNE 3, :45 12:30 Workshop Session: Anitschkow Hall Track 4: Advanced Clinical Seminars 4.2 OPTIMIZING TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA Chair: TBA Børge Nordestgaard, Denmark 11:45 TREATMENT OF ADULTS Luis Masana, Spain 12:05 TREATMENT OF CHILDREN AND ADOLESCENTS Albert Wiegman, The Netherlands 12:25 DISCUSSION 22
Sunday, March 22, 2015
SCIENTIFIC PROGRAMME (As of October 7, 2014) Sunday, March 22, 2015 12:00-13:30 Educational Symposium - Supported Session 12:00-13:30 Educational Symposium - Supported Session Hall B 13:30-14:00 Break
EAS Congress Innsbruck Highlights: A programme to excite, inspire and inform!
Press release 84 th European Atherosclerosis Society Congress, Innsbruck, Austria For circulation 29 th May, 2016. 84 th Annual Congress of the European Atherosclerosis Society (EAS) May 29 th - June 1
Familial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
HDL : A Treatment Target? ESC Paris M. John Chapman Ph.D., D.Sc., FESC. President, European Atherosclerosis Society
ESC Paris 2011 HDL : A Treatment Target? M. John Chapman Ph.D., D.Sc., FESC Director, Dyslipidemia and Atherosclerosis Research Unit, INSERM, University Pierre and Marie Curie, Hôpital de la Pitié-Salpetriere,
B. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
Lipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?
FOURIER STUDY Did the study achieve its main objective? 2 15% 1 5% 9.8% YES FOURIER compared Repatha with placebo in patients who were taking a statin and had hardening or narrowing of the arteries and
Lipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
Very high cholesterol from birth: are target LDL cholesterol levels now achievable with new treatments?
Press release 3 Madrid, May 3 st, 204 82 nd Annual Congress of the European Atherosclerosis Society (EAS) May 3-June 3, Madrid, Spain Very high cholesterol from birth: are target LDL cholesterol levels
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
Arteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
Pathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
Saturday, 11th February 2017
Friday, 10th February 2017 Opening Lecture Chairpersons: Karam Kostner and David Colquhoun Lipid Lowering Therapy: Exciting New Developments and Challenges 18:00-19:00 Peter Toth, University of Illinois
Defining Severe Familial Hypercholesterolemia. Raul D. Santos MD, PhD Brazil
Defining Severe Familial Hypercholesterolemia Raul D. Santos MD, PhD Brazil 1 Disclosure Honoraria received for consulting, speaker and or researcher activities : Astra Zeneca, Akcea, Amgen, Biolab, Esperion,
The TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
Adverse Effects of Statin Therapy: Perception versus the Evidence
Adverse Effects of Statin Therapy: Perception versus the Evidence Focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract A Consensus Statement from the European
Inhibition of PCSK9: The Birth of a New Therapy
Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein
ScreenPro FH: From the Czech MedPed to International Collaboration. ScreenPro FH Is a Participating Project
Physiol. Res. 66 (Suppl. 1): S85-S90, 2017 REVIEW ScreenPro FH: From the Czech MedPed to International Collaboration. ScreenPro FH Is a Participating Project of the EAS-FHCS R. CESKA 1,2, T. FREIBERGER
Central role of apociii
University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,
Prof. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
Management of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
Familial hypercholesterolaemia
Familial hypercholesterolaemia Jaimini Cegla MRCP FRCPath PhD Consultant in Chemical Pathology and Metabolic Medicine Hammersmith Hospital Lipid Clinic 20 April 2017 An unrecognised, potentially fatal,
Metabolic Syndrome. DOPE amines COGS 163
Metabolic Syndrome DOPE amines COGS 163 Overview - M etabolic Syndrome - General definition and criteria - Importance of diagnosis - Glucose Homeostasis - Type 2 Diabetes Mellitus - Insulin Resistance
Familial Hypercholesterolemia What a cardiologist should know
Institut für Klinische Chemie Arnold von Eckardstein Familial Hypercholesterolemia What a cardiologist should know Etiology of Hypercholesterolemia monogenic: (rare): e.g. familial hypercholesterolemia
Saturday, 8 September 2018 Treatment options and update on statin treatment Chair: M. Kayikcioglu, V. Kotsis How far should we lower LDL?
Friday, 7 September 2018 11.00-11.45 Registrations 11.45-12.00 Introduction - Welcome Messages L. Tokgozoglu, V. Kotsis Atherosclerosis and cardiovascular risk update Chair: A. Tselepis, H. Kultursay 12.00-12.30
DIABETES AND MACROVASCULAR DISEASE
Second International Course on DIABETES AND MACROVASCULAR DISEASE Lugano (CH), March 27-29, 2003 Scientific Programme Thursday, March 27, 2003 15.45 16.00 Opening Remarks Session 1: DIABETES MELLITUS A
Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins
Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number
6 th Hellenic Congress in Athens, of the Hellenic Atherosclerosis Society, on the December 2014
The Cardiovascular Medicine Journal, 2015, 9, 73-77 73 Open Access 6 th Hellenic Congress in Athens, of the Hellenic Atherosclerosis Society, on the 04-06 December 2014 Novel Pharmacologic Treatments of
Glossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein
Organized by. Scientific comittee
July 11 & 12, 2019 Institut Pasteur Organized by Arun Sanyal Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA Lawrence Serfaty Hôpital Hautepierre Hôpitaux Universitaires de
University of Parma - Karolinska Institutet IV Workshop on Lipid Metabolism and Vascular Biology
University of Parma - Karolinska Institutet IV Workshop on Lipid Metabolism and Vascular Biology Parma, Centro S. Elisabetta Campus Universitario 8-10 October, 2018 Organized by Franco Bernini (University
Second announcement. In addition, a pre-conference workshop on Lipidomics for biomarker and clinical analysis will take place during July 1-3, 2014.
Second announcement International conference: Healthcare integrated biobanking and multiomics biomarker analysis (July 3-5, 2014) Workshop: Lipidomics for biomarker and clinical analysis (July 1-3, 2014)
Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
LLL Session - Nutrition support in diabetes and dyslipidemia. Dyslipidemia: targeting the management of cardiovascular risk factors. M.
ESPEN Congress Leipzig 2013 LLL Session - Nutrition support in diabetes and dyslipidemia Dyslipidemia: targeting the management of cardiovascular risk factors M. Leon Sanz (ES) Dyslipidemia: Targeting
THURSDAY, 30 JUNE, 2016 FRIDAY, 1 JULY 2016
THURSDAY, 30 JUNE, 2016 18:00 18:30 OPENING CEREMONY Opening Lecture: TBA 18:30 19:30 Chairs: Maciej Banach (); Nathan D. Wong (Irvine, USA) 19:30 Get Together Reception FRIDAY, 1 JULY 2016 08:30 - Plenary
Chapter 18. Diet and Health
Chapter 18 Diet and Health Risk Factors and Chronic Diseases Interrelationships among Chronic Diseases Chronic Disease Heart Disease and Stroke Hypertension Cancer Diabetes The Formation of Plaques in
Modern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
A real life example In human studies, we quantify ~120 plasma related proteins Monocytes MMP9 Macrophages TNFα IL1ß platelet derived growth factor IFNγ MMP1 MMP8 MMP13 Myeloid Related Protein14 CD40
Cardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
July 5 & 6, 2018, Paris SCIENTIFIC PROGRAM
www.paris-nash.org Dear Colleagues, We are delighted to announce the 4th Paris NASH Meeting to be held on July 5-6 th 2018. This international academic meeting is aimed to do a deep-dive into many aspects
*Carbohydrate & Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa
Tuesday, May 26, 2015 Clinical Breakthroughs: Modifying LDL Cholesterol to Prevent CV Events International Society of Atherosclerosis, Amsterdam, Netherlands Long-term Treatment With Evolocumab in Patients
Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry
Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Learning Objectives 1. Define lipoproteins and explain the rationale of their formation in blood. 2. List different
EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial
EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial RP Giugliano, F Mach, K Zavitz, AC Keech, TR Pedersen, MS Sabatine, P Sever, C Kurtz, N Honarpour, BR Ott, on behalf of the EBBINGHAUS
Summary and concluding remarks
Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated
PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia
: 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University
Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
Evaluating Residual Risk and Long-term Management of the Young CHD Patient. The Arterial Wall
Evaluating Residual Risk and Long-term Management of the Young CHD Patient Patrick M Moriarty, M.D., Professor of Medicine Director of Clinical Pharmacology, Atherosclerosis and Lipoprotein-apheresis Center
ADVENTURES IN THE LIPIDOME
Organizing Committee: INTERNATIONAL SCHOOL OF PHARMACOLOGY ADVENTURES IN THE LIPIDOME Erice, Sicily, 26 th - 30 th September 2017 Garret FitzGerald, Philadelphia, USA Pietro Minuz, Verona, Italy Carlo
V Barcelona International Congresson the. Mediterranean. Diet. Preliminar Programme March, 9, 10 and 11, 2004 in: Organized by:
V Barcelona International Congresson the Mediterranean Diet Preliminar Programme March, 9, 10 and 11, 2004 in: Organized by: GOALS andobjectives The healthy benefits of the Mediterranean Diet continue
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American
Evan A. Stein 1, David Sullivan 2, Anders G. Olsson 3, Rob Scott 4, Jae B. Kim 4, Allen Xue 4, Thomas Liu 4, Scott M. Wasserman 4
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo and Ezetimibe Controlled Study Evan A. Stein 1, David Sullivan
Best Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az
Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of
Program Monday Sept 4 th, Tuesday Sept 5 th
Program Monday Sept 4 th, Tuesday Sept 5 th Monday, Sept. 4 th 16:00 18.00 Arrival and registration 18:00 20:00 Dinner 20:00-20:05 Welcome and introduction of Keynote Lecturer Anne Tybjærg-Hansen (Copenhagen,
PCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
Learning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?
Scott J. Soifer, MD Professor and Vice Chair Department of Pediatrics University of California, San Francisco UCSF Benioff Children s Hospital Cholesterol and Lipids in Kids: It s a Matter of the Heart
Complications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
Disclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values
39 th National Conference on Pediatric Health Care Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA March 19-22, 2018 CHICAGO Disclosures Speakers Bureau Sanofi and Regeneron Learning Objectives
Cholesterol, Heart Attack and Stroke. Dr Tai E Shyong Consultant Department of Endocrinology Singapore General Hospital
Cholesterol, Heart Attack and Stroke Dr Tai E Shyong Consultant Department of Endocrinology Singapore General Hospital Outline Why are we interested in cholesterol What is a heart attack and how does it
40 th Annual Scientific meeting of the European Lipoprotein Club 4-7 September 2017 PRELIMINARY PROGRAMME
40 th Annual Scientific meeting of the European Lipoprotein Club 4-7 September 2017 PRELIMINARY PROGRAMME Monday afternoon, September 4 th 14.00-16.00 Organizing Committee meeting 16.00-18.00 Arrival and
PCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2
Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia
PCSK9 inhibition in homozygous familial hypercholesterolaemia
PCSK9 inhibition in homozygous familial hypercholesterolaemia Slide deck kindly supplied as an educational resource by Dr Evan A Stein MD PhD Director Emeritus Metabolic & Atherosclerosis Research Center
Company Overview. September 2018 NASDAQ: MDGL
Company Overview September 2018 NASDAQ: MDGL 1 Forward Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our future financial or business
Finnish Atherosclerosis Society Suomen Ateroskleroosiyhdistys ry
19.2.2017 program Finnish Atherosclerosis Society Suomen Ateroskleroosiyhdistys ry Time: Friday 17.3.2017 Photograph by Hannu Uusitalo Place: The lecture hall of the Department of Pharmacology F202, Door
Tracking a Killer Molecule
Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive
BRIDGING THE GAPS IN CARE OF FAMILIAL HYPERCHOLESTEROLEMIA
BRIDGING THE GAPS IN CARE OF FAMILIAL HYPERCHOLESTEROLEMIA Co-chairs: Christie Ballantyne, MD and John Chapman, PhD, DSc *** Monday, October 13 th Breakfast and Registration: 7:00am-8:00am Welcome.8:00am-8:25am
Review of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
PCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
Nature Genetics: doi: /ng.3561
Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating
Drug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
CLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
Nephrologisches Zentrum Göttingen GbR Priv. Doz. Dr. med. V. Schettler
Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9- Inhibitors, Lipoprotein Apheresis or
WORKSHOP 1. Management of Patients with Familial Hypercholesterolemia
WORKSHOP 1 Management of Patients with Familial Hypercholesterolemia Tutors: Manal Al-Kindi (Oman)/ Gilles Lambert (France) (Case 1) Zuhier Awan (KSA)/ Raul Santos (Brazil) (Case 2) Khalid Al-Waili (Oman)/
FOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
Drug Class Prior Authorization Criteria PCSK9 Inhibitors
Drug Class Prior Authorization Criteria PCSK9 Inhibitors Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
Glossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"
March 30, 2014, Joint ACC/JAMA Late-breaking Clinical Trials Session 402 American College of Cardiology, Washington DC
A Phase 3 Double-blind, Randomized Study to Assess Safety and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of Statin Erik Stroes 1, David Colquhoun
INC International Nut & Dried Fruit Council Symposium Nuts in Health and Disease. Granada, 19 th September 2013 Press Kit
INC International Nut & Dried Fruit Council Symposium Nuts in Health and Disease Granada, 19 th September 2013 Press Kit Index Introduction Keynote Speakers Conference Abstract Useful Information The International
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
Approach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
PROGRAMME BOOK 86TH CONGRESS. LISBON PORTUGAL May 05-08, 2018
PROGRAMME BOOK www.eas2018.com 86TH CONGRESS LISBON PORTUGAL May 05-08, 2018 87TH EAS CONGRESS MAASTRICHT May 26-29, 2019 THE NETHERLANDS KEY DATES September 17, 2018 Abstract submission opens December
Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD
Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J Koren 1, Robert P Giugliano 2, Frederick Raal 3, David
An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
Targeting the High-Risk Patient
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
Farmaci innovativi in ambito cardiovascolare: considerazioni di Farmacologia. Prof. Alberto Corsini University of Milan, Italy
Farmaci innovativi in ambito cardiovascolare: considerazioni di Farmacologia Prof. Alberto Corsini University of Milan, Italy Outline of the presentation State of the art on statin therapy Explore unmet
Plant sterols/stanols for cholesterol lowering and prevention of cardiovascular disease
Plant sterols/stanols for cholesterol lowering and prevention of cardiovascular disease Prof Dr Elke A. Trautwein, Senior Scientist Cardiovascular Health, Unilever, on behalf of the International Plant
High density lipoprotein metabolism
High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC